T. Pages, B.R. Langlois / Journal of Fluorine Chemistry 107 (2001) 321±327
327
[4] P. Morrish, J. Rakshi, D.J. Brooks, in: D. Comar (Ed.), PET for Drug
Development and Evaluation, Kluwer Academic Publishers, Dor-
drecht, 1995, pp. 179±188.
5 min more at 108C and immersed for the required time in
an oil bath preheated at 908C.
[5] P. Damhaut, Contribution to the synthesis of
radiopharmaceuticals for the in vivo study of the dopaminergic
Á
system with PET, Ph.D. Thesis, University of Liege, Belgium, 1994.
[
18F]fluorinated
3.4. Common work up
[6] K. Jorga, K.L. Leenders, I. GuÈnther, M. Psylla, in: D. Comar (Ed.),
PET for Drug Development and Evaluation, Kluwer Academic
Publishers, Dordrecht, 1995, pp. 189±195.
After cooling, 0.3 M aqueous KOH (5 ml) was added and
the two phases were separated. The aqueous phase was
extracted with ethyl ether (3 Â 5 ml) and the collected
organic phases were washed with water (3 Â 5 ml), dried
over Na2SO4 and ®ltered.
[7] M.L. Gross, D.H. Blank, W.M. Welch, J. Org. Chem. 58 (1993) 2104.
[8] M.D. Theadhill, M.F.G. Stevens, Synthesis (1983) 289.
[9] O. Wallach, Justus Liebigs Ann. Chem. (1886) 233 and 255.
[10] B. Langlois, in: B. Baasner, H. Hagemann, J.C. Tatlow (Eds.),
Houben±Weyl Methods of Organic Chemistry, Vol. E10a, Thieme,
Stuttgart, 1999, Chapter 26, pp. 686±740.
3.5. Analyses
[11] P.J. Das, S. Khound, Tetrahedron 50 (1994) 9107.
[12] J.S. Ng, J.A. Katzenellenbogen, M.R. Kilbourn, J. Org. Chem. 46
(1981) 2520.
Most of reaction media were analysed by GC with an
internal standard (4-chloro¯uorobenzene) against which
most of the simplest products have been calibrated. These
products were either commercially available or prepared
according to the literature (4-methyltri¯ate, 4-(tri¯uor-
oethoxy)acetophenone). Some reaction media were also
analysed by 19F NMR with an internal standard (PhOCF3).
[13] M.N. Rosenfeld, D.A. Widdowson, J. Chem. Soc., Chem. Commun.
(1979) 914.
[14] T.J. Tewson, M.J. Welch, J. Chem. Soc., Chem. Commun. (1979) 1149.
[15] J.R. Barrio, N. Satyamurphy, H. Ku, M.E. Phelps, J. Chem. Soc.,
Chem. Commun. (1983) 443.
[16] N. Satyamurphy, J.R. Barrio, D.G. Schmidt, C. Kammerer, G.T. Bida,
M.E. Phelps, J. Org. Chem. 55 (1990) 4560.
[17] C. Galli, Chem. Rev. 88 (1988) 765.
[18] Y. Hirose, G.H. Wahl, H. Zollinger, Helv. Chim. Acta 59 (1976) 1427.
References
È
È
[19] F. Trondlin, C. Ruchardt, Chem. Ber. 110 (1977) 2494.
[20] H. Zollinger, Angew. Chem. Int. Ed. Eng. 17 (1978) 141.
[21] H. Loewenschuss, G.H. Wahl Jr., H. Zollinger, Helv. Chim. Acta 59
(1976) 1438.
[1] D. Comar, PET for Drug Development and Evaluation, Kluwer
Academic Publishers, Dordrecht, 1995.
[2] J.S. Fowler, in: R. Filler, Y. Kobayashi, L.M. Yagupolskii (Eds.),
Organofluorine Compounds in Medicinal Chemistry and Biomedical
Applications, Elsevier, Amsterdam, 1993, pp. 309±338.
[22] P. Burri, H. Loewenschuss, H. Zollinger, Helv. Chim. Acta 57 (1974)
395.
[23] I. Szele, H. Zollinger, Helv. Chim. Acta 61 (1978) 1721.
[24] Y. Hashida, R.G.M. Landells, G.E. Lewis, I. Szele, H. Zollinger, J.
Am. Chem. Soc. 100 (1978) 2816.
[3] Y.S. Ding, J.S. Fowler, Biomedical frontiers of fluorine chemistry, in:
I. Ojima, J.R. McCarthy, J.T. Welch (Eds.), Proceedings of the ACS
Symposium Series 639, American Chemical Society, Washington,
DC, 1996, Chapter 23, pp. 328±343.
[25] C. RuÈchardt, E. Merz, B. Freudenberg, H.J. Opgenorth, C.C. Tan, R.
Werner, Chem. Soc. Spectrosc. Pub. 24 (1970) 51.